-final study leading to full Canadian license for the vaccine-
BELLEVILLE, ON, May 5 /CNW/ - Bioniche Life Sciences Inc. (TSX: BNC)
(ASX: BNC), a research-based, technology-driven Canadian
biopharmaceutical company, today announced that the results of a
controlled challenge study with the Company's Escherichia coli (E. coli) O157 cattle vaccine -EconicheTM - have been published in this month's issue of The Canadian Journal of Veterinary Research (2011;75:98-105), a peer-reviewed scientific journal.
The article, entitled, "Vaccination with type III secreted proteins
leads to decreased shedding in calves after experimental infection with
Escherichia coli O157", was co-authored by Kevin J. Allen, Dragan Rogan, B. Brett Finlay,
Andrew A. Potter, David J. Asper. This article summarized a controlled
challenge study conducted in early 2008 at the Vaccine and Infectious
Disease Organization (VIDO) - University of Saskatchewan which was the
final study that led to the full Canadian license for EconicheTM from the Canadian Food Inspection Agency (CFIA) in October, 2008.
The controlled challenge study at VIDO involved 30 placebo-treated cows
and 30 vaccinated cows. The vaccinated cows each received three doses
of EconicheTM. Both groups were then infected with E. coli O157 and fecal shedding was monitored daily for a two-week period. These
data indicate that EconicheTM vaccination had protective effects through significant reductions in
both the number of animals shedding and the number of challenge
organisms shed per animal. The authors of the article summarized the
study by saying it provides evidence that vaccination with EconicheTM is an effective pre-harvest intervention strategy against E. coli O157.
These data constitute part of the Company's international regulatory
dossier in such jurisdictions as Australasia, Europe, Scandinavia, and
South America. The Company has been actively exploring opportunities to
introduce EconicheTM to markets beyond North America, where it has a full license (Canada)
and a pending conditional license (U.S.).
EconicheTM will be manufactured in the Company's newly completed Animal Health and
Food Safety Vaccine Manufacturing Centre in Belleville, Ontario,
currently undergoing validation and commissioning. Full production in
the new Centre is expected to begin by the fall of 2011.
About the Bioniche E. coli O157 Vaccine (EconicheTM)
The Food Safety Division of Bioniche Life Sciences Inc. has worked with
Canadian university researchers, in particular, inventor Dr. Brett
Finlay and his team at the University of British Columbia, to develop
and license a cattle vaccine against E. coli O157. This vaccine - trademarked EconicheTM - is meant to reduce the level of the bacterium in water, food and the
environment and, in turn, reduce the potential infection of humans.
EconicheTM has the potential to significantly reduce the amount of E. coli O157 shed into the environment by beef and dairy cattle. This organism
does not cause illness in cattle, but cattle are the primary reservoir
for it. Vaccination of cattle with EconicheTM can help reduce the risk of food and waterborne contamination with E. coli O157.
EconicheTM has been developed by a strategic alliance formed in September, 2000
and composed of the University of British Columbia (UBC), the Alberta
Research Council (ARC), the University of Saskatchewan's Vaccine and
Infectious Disease Organization (VIDO), and Bioniche, which holds the
rights for worldwide commercialization of the vaccine.
More about E. coli O157
The E. coli O157 organism causes no disease in cattle, but cattle are the primary
reservoir for it. E. coli O157 can cause severe illness and can even be fatal when ingested by
humans from contaminated meat, vegetables, other food products, or
water. Human exposure and infection with E. coli O157 can result in serious health consequences, including abdominal
pain and severe bloody diarrhea. In severe cases, kidney damage can
occur and progress to serious complications and even death. Lingering,
long-term medical conditions can persist in individuals exposed to the
bacterium. These include post-infectious irritable bowel syndrome
(PI-IBS), reduced kidney function, diabetes, hypertension and reactive
An estimated 100,000 cases of human infection with the E. coli O157 organism are reported each year in North America. Two to seven per
cent of those people develop haemolytic uremic syndrome (HUS), a
disease characterized by kidney failure. Five percent of HUS patients
die, many of them children and senior citizens, whose kidneys are more
sensitive to damage.
About Bioniche Life Sciences Inc.
Bioniche Life Sciences Inc. is a research-based, technology-driven
Canadian biopharmaceutical company focused on the discovery,
development, manufacturing, and marketing of proprietary products for
human and animal health markets worldwide. The fully-integrated company
employs more than 200 skilled personnel and has three operating
divisions: Human Health, Animal Health, and Food Safety. The Company's
primary goal is to develop proprietary cancer therapies supported by
revenues from marketed products in human and animal health. For more
information, please visit www.Bioniche.com.
Except for historical information, this news release may contain
forward-looking statements that reflect the Company's current
expectation regarding future events. These forward-looking statements
involve risk and uncertainties, which may cause, but are not limited
to, changing market conditions, the successful and timely completion of
clinical studies, the establishment of corporate alliances, the impact
of competitive products and pricing, new product development,
uncertainties related to the regulatory approval process, and other
risks detailed from time to time in the Company's ongoing quarterly and
SOURCE Bioniche Life Sciences Inc.
For further information:
Jennifer Shea, Vice-President, Communications, Investor & Government Relations
Bioniche Life Sciences Inc.
Telephone: (613) 966-8058; from Australia: 0011 1 613-966-8058
Cell: (613) 391-2097; from Australia: 0011 1 613-391-2097